Quarterly report pursuant to Section 13 or 15(d)

INVESTMENT (Details Narrative)

INVESTMENT (Details Narrative) - USD ($)
3 Months Ended
Mar. 12, 2021
Mar. 31, 2021
Dec. 31, 2020
Dec. 31, 2018
Equity Method Goodwill   $ 5,000,000    
Aggregate investment   6,000,000    
Equity investment   3,440,000 $ 3,650,000  
Convertible note investment   1,000,000    
ILiAD [Member]        
Advisory and legal expenses       $ 41,000
Equity investment - net loss   $ (210,000)    
ILiAD [Member] | Class C units [Member]        
Ownership percentage fully diluted   7.60%    
Ownership percentage - non fully diluted   9.50%    
ILiAD [Member] | Maximum [Member]        
Aggregate investment   $ 6,000,000    
ILiad Biotechnologies LLC [Member]        
Maximum convertible debt offering $ 23,500,000      
Interest rate 6.00%      
Notes conversion, description The Notes have a maturity of three years with interest accruing at 6% per annum. The Notes are required to be converted into a Qualified Financing (minimum financing of $15 million) at the lesser of (i) 80% of the price paid per unit in such offering or (ii) a price based on an enterprise value of $176,000,000. In addition, the Notes shall convert in the event of a merger at the lower of an enterprise value of $176,000,000 or the stated valuation of ILiAD in the merger transaction. In the event of a change-in-control, noteholders will also have the option to have the Notes repaid except in a Qualified Offering or a stock-for-stock merger.      
Additional convertible note investment $ 1,000,000